UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Annals of oncology, 2019-04, Vol.30 (4), p.551-557

2019

Volltextzugriff (PDF)

The role of dendritic cell precursors in tumour vasculogenesis

British journal of cancer, 2005-04, Vol.92 (7), p.1182-1187

2005

Volltextzugriff (PDF)

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Gynecologic oncology, 2012-04, Vol.125 (1), p.136-140

2012

Volltextzugriff (PDF)

Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer

Gynecologic oncology, 2022-01, Vol.164 (1), p.129-135

2022

Volltextzugriff (PDF)

The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo

Molecular and Cellular Biology, 1997-06, Vol.17 (6), p.3194-3201

1997

Volltextzugriff (PDF)

Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A

Nature medicine, 2004-09, Vol.10 (9), p.950-958

2004

Volltextzugriff (PDF)

Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system

Neuron (Cambridge, Mass.), 1993-10, Vol.11 (4), p.657-672

1993

Volltextzugriff (PDF)

Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy

Annals of hematology, 2002-07, Vol.81 (7), p.410-413

2002

Volltextzugriff (PDF)

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies

The Journal of neuroscience, 1996-02, Vol.16 (3), p.1114-1122

1996

Volltextzugriff (PDF)

Nova-1 Regulates Neuron-Specific Alternative Splicing and Is Essential for Neuronal Viability

Neuron (Cambridge, Mass.), 2000-02, Vol.25 (2), p.359-371

2000

Volltextzugriff (PDF)

Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma

Human gene therapy, 2005-06, Vol.16 (6), p.765-778

2005

Volltextzugriff (PDF)

Abstract AP17: OVARIAN TUMOR STIMULATION CONVERTS NORMAL OVARY AND OMENTAL MESENCHYMAL STEM CELLS INTO TUMOR–PROMOTING CARCINOMA–ASSOCIATED MESENCHYMAL STEM CELLS

Clinical cancer research, 2017-06, Vol.23 (11_Supplement), p.AP17-AP17

2017

Volltextzugriff (PDF)

Vascular leukocytes contribute to tumor vascularization

Blood, 2005-01, Vol.105 (2), p.679-681

2005

Volltextzugriff (PDF)

Transcriptional coactivator Drosophila Eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth

Cancer research (Chicago, Ill.), 2005-02, Vol.65 (3), p.925-932

2005

Volltextzugriff (PDF)

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Annals of oncology, 2019-04, Vol.30 (4), p.551

2019

Volltextzugriff (PDF)

Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5008-5008

2011

Volltextzugriff (PDF)

Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells

Cancer research (Chicago, Ill.), 2004-03, Vol.64 (6), p.2175-2182

2004

Volltextzugriff (PDF)

Endothelin receptor B predicts poor prognosis in epithelial ovarian cancer (EOC) and can be inhibited to increase intratumoral T cells and enhance tumor vaccine therapy

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2524-2524

2006

Volltextzugriff (PDF)

LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells

Cancer biology & therapy, 2003-07, Vol.2 (4), p.446-451

2003

Volltextzugriff (PDF)

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies

The Journal of neuroscience, 1996-01, Vol.16 (3), p.1097-1105

1996

Volltextzugriff (PDF)

Ovarian cancer stem cells: Working towards the root of stemness

Cancer letters, 2013-09, Vol.338 (1), p.147-157

2013

Volltextzugriff (PDF)

Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production

The Journal of clinical investigation, 2011-08, Vol.121 (8), p.3206-3219

2011

Volltextzugriff (PDF)

Metformin targets ovarian cancer stem cells in vitro and in vivo

Gynecologic oncology, 2012-11, Vol.127 (2), p.390-397

2012

Volltextzugriff (PDF)

Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays

Gynecologic oncology, 2015-07, Vol.138 (1), p.181-189

2015

Volltextzugriff (PDF)

Ovarian cancer stem cell markers: Prognostic and therapeutic implications

Cancer letters, 2012-09, Vol.322 (1), p.1-7

2012

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(28)
Female
(25)
Oncology
(19)
Animals
(18)
Mice
(18)
Ovarian Neoplasms - Pathology
(13)
Ovarian Cancer
(12)
Tumors
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(9)
Ovarian Neoplasms - Metabolism
(9)
Cell Line, Tumor
(8)
Ovarian Neoplasms - Drug Therapy
(8)
Ovarian Neoplasms - Genetics
(8)
Hematology, Oncology And Palliative Medicine
(7)
Neoplastic Stem Cells - Metabolism
(6)
Obstetrics & Gynecology
(6)
Stem Cells
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

The role of dendritic cell precursors in tumour vasculogenesis

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer

The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo

Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A

Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system

Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies

Nova-1 Regulates Neuron-Specific Alternative Splicing and Is Essential for Neuronal Viability

Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma

Abstract AP17: OVARIAN TUMOR STIMULATION CONVERTS NORMAL OVARY AND OMENTAL MESENCHYMAL STEM CELLS INTO TUMOR–PROMOTING CARCINOMA–ASSOCIATED MESENCHYMAL STEM CELLS

Vascular leukocytes contribute to tumor vascularization

Transcriptional coactivator Drosophila Eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT)

Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells

Endothelin receptor B predicts poor prognosis in epithelial ovarian cancer (EOC) and can be inhibited to increase intratumoral T cells and enhance tumor vaccine therapy

LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies

Ovarian cancer stem cells: Working towards the root of stemness

Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production

Metformin targets ovarian cancer stem cells in vitro and in vivo

Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays

Ovarian cancer stem cell markers: Prognostic and therapeutic implications

Suchergebnisse filtern